Trial reportBMC oral health2025
Effect of the recombinant amelogenin peptide TRAP on remineralization of early enamel caries: an in-situ study.
Trial report in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging trends in enamel remineralization.Bioinformation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe tyrosine-rich amelogenin peptide (TRAP) is the main enzymatic hydrolysis product of amelogenin during enamel development. The TRAP peptide has been shown to promote the remineralization of early enamel caries in vitro. The aim of this crossover blinded and randomized study was to evaluate the impact of recombinant amelogenin peptide TRAP on the remineralization of initial enamel caries lesions in situ.
methodsThe binding capacity of recombinant amelogenin peptide TRAP to hydroxyapatite (HA) and a demineralized enamel surface was analyzed by a Langmuir adsorption isotherm experiment and confocal laser scanning microscopy (CLSM). Subsequently, the remineralization effect of recombinant amelogenin peptide TRAP on initial enamel carious lesions was studied using an in situ caries model. In this randomized, crossover, and blinded study, 12 volunteers wearing intraoral removable in-situ appliances with one bovine enamel block were divided into three groups: Group A received deionized water (DDW, negative control); Group B received recombinant amelogenin peptide TRAP (100 µg/ml); Group C received sodium fluoride (2 ppm). The study took place over three periods of 14 days each. At the end of each treatment period, the percentage of surface microhardness recovery (%SHR) and the integrated change in subsurface hardness (%ΔIHC) were evaluated.
resultsRecombinant amelogenin peptide TRAP adsorbed onto HA and demineralized enamel surfaces. After in situ analysis, all samples hardened significantly compared with baseline. Fluoride had a significantly greater effect than all other treatments. %SMHR was significantly greater than the DDW for the recombinant amelogenin peptide TRAP. Considering subsurface remineralization, treatment with recombinant amelogenin peptide TRAP and fluoride promoted increases of 6.73% and 15.68%, respectively, in %ΔIHC compared with DDW.
conclusionRecombinant amelogenin peptide TRAP can promote the remineralization of early enamel caries lesions in situ. CLINICAL RELEVANCE: This study demonstrated the potential of recombinant amelogenin peptide TRAP to assist in the remineralization of artificial carious lesions in situ. The amelogenin peptide TRAP may be a promising, non-fluorinated, biomimetic, remineralization anti-caries agent. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.